Advances in gene editing and DNA synthesis technologies are accelerating biotech innovation. Companies are pursuing novel editing platforms that improve precision and extend beyond CRISPR, while enzymatic and microchip-based DNA synthesis systems enable scalable, massively parallel construction of complex sequences. These developments are complemented by AI-driven approaches to optimize protein production in manufacturing cells, promising enhanced efficiency in therapeutic molecule development and commercial bioproduction.